ArticleFrontiers in oncology2022
Development and Validation of a Novel Model to Predict Regional Lymph Node Metastasis in Patients With Hepatocellular Carcinoma.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Efficacy of radiation therapy plus targeted therapy with or without immunotherapy for lymph node metastases in hepatocellular carcinoma.Hepatology international · 2026Article
- Novel models for predicting individualized outcomes in patients with advanced hepatocellular carcinoma receiving immunotherapy.Frontiers in oncology · 2026Article
- Case report of curative resection after preoperative bevacizumab and sintilimab therapy in hepatocellular carcinoma with lymph node metastasis.Discover oncology · 2025Article
- Role of the transcription factorTranslational cancer research · 2025Article
- Correlation between clinical and pathological nodal status in hepatocellular carcinoma: identifying risk factors for lymph node metastasis via the national cancer database.World journal of surgical oncology · 2025Article
- Development and validation of machine learning models for distant metastasis of primary hepatic carcinoma: a population-based study.Discover oncology · 2025Article
- Research Progress of Dual-energy CT in Diagnosis and Evaluation of Curative Effect of Liver Cancer: A ReviewCurrent medical imaging · 2025Review
- Factor Analysis of the Effect of Hepatitis B-Related Liver Cancer Treatment Efficacy.Journal of hepatocellular carcinoma · 2025Article
- Development and evaluation of a nomogram prediction model for invasion and metastasis in primary liver cancer based on serum CD147 and IL-6.Frontiers in oncology · 2025Article
- The Role of Lymphadenectomy in the Surgical Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Cancers · 2024Review
- Comparison of metastasis and prognosis between early-onset and late-onset hepatocellular carcinoma: A population-based study.Heliyon · 2024Article
- Head-to-head comparison ofCancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Establishment and Clinical Application of the Nomogram Related to Risk or Prognosis of Hepatocellular Carcinoma: A Review.Journal of hepatocellular carcinoma · 2023Review
- Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database.BMC gastroenterology · 2022Article
- Epidemiological and Clinical Characteristics of Five Rare Pathological Subtypes of Hepatocellular Carcinoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe evaluation of the nodal status of hepatocellular carcinoma (HCC) is a classic but controversial topic. This study aimed to investigate the incidence of lymph node metastasis (LNM), explore the role of lymph node dissection (LND), and develop and validate a novel model to predict LNM in patients with HCC, not other specified (NOS).
methodsThe study cohort was taken from the Surveillance, Epidemiology, and End Results database. The annual percent change (APC) was calculated using the Joinpoint regression. Survival analyses adopted the competing risk model. The nomogram was constructed based on the least absolute shrinkage and selection operator (LASSO) logistic regression algorithm and validated by calibration curves. The area under the receiver operating characteristic curve (AUROC) was obtained to compare prognostic performance. Decision curve and clinical impact curve analyses were introduced to examine the clinical value of the models.
resultsA total of 8,829 patients were finally enrolled in this study, and 1,346 (15.2%) patients received LND. The LND rate showed no noticeable fluctuation in the last decade, with an APC of 0.5% (P=0.593). LNM was identified in 56 (4.2%) patients and confirmed an independent prognostic factor of HCC patients (P=0.005). There were 2,497 lymph nodes retrieved, and 93 (3.7%) of them were positive. After propensity score matching, LND indicated no direct oncologic benefit and did not worsen competing risks. Moreover, an increased number of lymph nodes retrieved could not improve prognoses. 1,346 patients with LND were further randomly divided into the training and validation sets with the ratio of 1:1. Race, tumor size, clinical T stage, extrahepatic bile duct invasion, and tumor grade were independent risk factors for LNM. The constructed model was well calibrated and showed good discrimination power and net benefits in clinical practice.
conclusionLNM is an independent prognostic factor in HCC, but routine LND seems to be unnecessary in HCC patients. The constructed model could predict the presence of LNM in HCC patients with good performance, which is meaningful to patient stratification and individual treatment strategies optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.